4DMedical

What 4DMedical does

4DMedical is a medical technology company specializing in advanced respiratory imaging, functional lung imaging, and pulmonary disease assessment. It develops software that transforms routine chest CT and X-ray imaging into quantitative, regional lung-function insights for clinicians, researchers, hospitals, and life sciences partners. Their imaging solutions, including CT:VQ™, support non-contrast ventilation and perfusion assessment, aiding in the evaluation of conditions such as COPD, emphysema, pulmonary embolism, and other chronic lung diseases. By combining medical imaging software with quantitative image analysis and streamlined clinical workflows, 4DMedical supports the visualization and assessment of lung ventilation, perfusion, V/Q relationships, and regional pulmonary function. The company's mission is to make lung health assessment more accessible and quantitative, improving outcomes for people with lung disease.

Products

• CT:VQ™World’s first non-contrast post-processing technology that transforms routine chest CTs into quantitative, lobar ventilation (V) and perfusion (Q) maps without injected contrast or radioisotopes. Delivered via software-as-a-service, results are returned directly into the radiology workflow for interpretation alongside the source CT images.
• XV TechnologyBreakthrough functional lung imaging technology that enables non-invasive diagnosis and tailored treatment options from standard X-ray scans, particularly for veterans exposed to airborne toxins.
• Lung Health Imaging PanelDesigned to expand the value of a thoracic CT by producing additional quantitative outputs relevant to broader cardiopulmonary health. Components include LDAi, CAC, IQ-UIP, and lung cancer screening tools.
• LDAi (Lung Density Analysis–Inspiration)Quantitative measures relevant to emphysema assessment, part of the Lung Health Imaging Panel.
• CAC (Coronary Artery Calcification)Quantification of a widely used imaging marker associated with cardiovascular risk, utilizing advanced artificial intelligence to identify and quantify coronary artery calcification from non-contrast chest CT imaging. Part of the Lung Health Imaging Panel and a standalone product.
• IQ-UIPQuantitative analysis intended to support clinician review of imaging features that may be present in patterns consistent with UIP, part of the Lung Health Imaging Panel.
• CT LVAS™ (Computed Tomography Lung Ventilation Analysis Software)Image processing software that operates on CT scans to provide functional lung health detail, quantifying regional lung ventilation and ventilation heterogeneity in a comprehensive report with 4D visualizations. Requires paired deep-inspiratory and expiratory breath-hold volumetric CTs.
• LDAf™Associated with restrictive & obstructive lung diseases, paired with CT LVAS for additional insights.
• LTA™Lung Texture Analysis.
• PHA™Product manufactured by Imbio, a subsidiary of 4DMedical.

Key capabilities

• Non-contrast ventilation and perfusion assessment
• Quantitative, regional lung-function insights
• Software transforms routine chest CT and X-ray imaging
• Visualization and assessment of lung ventilation, perfusion, V/Q relationships
• Color V and Q overlays registered to CT anatomy
• Quantitative Metrics (Total Lung Volumes, Lobar Distribution)
• AI-Powered Detection for CAC
• Agatston Score (AS) for CAC
• Arterial Age for CAC
• Lesion Count, Volume, and Mass for CAC
• 3D Visualizations for CAC
• Regional quantification of lung function (Lung Volumes, Ventilation Heterogeneity (VH), Ventilation Defect Percentage (VDP))
• Easy-to-read, color-coded visualization of regional lung ventilation
• Uses existing hospital imaging equipment
• SaaS delivery model

Use cases

• Evaluation of COPD
• Evaluation of emphysema
• Evaluation of pulmonary embolism (PE workups)
• Evaluation of other chronic lung diseases
• CTEPH assessment
• Regional detection of V/Q abnormalities
• BLVR planning
• Pre-op assessment
• Longitudinal monitoring of lung conditions
• Functional interpretation to non-contrast chest CTs
• Expanding access to V/Q imaging across existing CT infrastructure
• Supporting assessment and follow-up for regional lung characteristics
• Emphysema assessment (LDAi)
• Cardiovascular risk assessment (CAC)
• Supporting clinician review of imaging features consistent with UIP (IQ-UIP)
• Lung cancer screening programs
• Diagnosis and treatment of respiratory injury in veterans exposed to airborne toxins
• Characterizing lung conditions and detecting associated regional lung changes
• Cardiothoracic risk assessment
• Triage unexplained dyspnea to determine/rule-out source of symptoms
• Population Health Screening: Incidental CAC detection on all eligible chest CTs across health systems

AI approach

4DMedical develops software that transforms routine chest CT and X-ray imaging into quantitative, regional lung-function insights. Their products like CT:VQ™ and CAC™ utilize advanced artificial intelligence to analyze medical images for conditions such as COPD, emphysema, pulmonary embolism, and coronary artery calcification. They build their own proprietary models for image analysis.

Tech named: artificial intelligence, quantitative image analysis

Industries served

• Medical Equipment Manufacturing
• Healthcare
• Life Sciences

What it says sets it apart

• Non-contrast imaging (no IV access, no radioisotopes, no contrast agents)
• Accessible at scale (runs on existing CT scanners)
• Patient- and operations-friendly (single CT appointment, simplified scheduling, avoids contrast media)
• Transforms routine chest CTs into quantitative, lobar ventilation and perfusion maps
• Provides functional lung health detail not available by other modalities
• AI-powered detection for CAC
• FDA-Cleared (CT:VQ™, CAC)
• TGA Approval (CT:VQ™)
• CE Mark Certified (CAC)
• ARTG approval pending (CAC)
• Eligible for reimbursement in the US under Category III CPT codes (CT:VQ™)
• Veteran-led company with a deep understanding of lung health issues affecting military personnel

Funding rounds we track

From the AI funding tracker — rounds as reported by the linked publications.